• Home
  • Our Capabilities
  • Our People
    • Naomi Pearce
    • Jacinta Flattery O’Brien PhD
    • Jennifer Enmon PhD JD
    • Grant Shoebridge PhD
    • Kadri Elcoat
    • Kate Legge
    • Lesley White
    • Alex May
    • Christopher Coates
    • Jessica Chadbourne PhD
    • Joanne Grant
    • Emily Bristow
    • Brittany Deleon
    • Erni Othman
    • Amber Cross
  • News
    • Pearce IP Blog
    • BioBlast®
  • Blog
  • BioBlast®
  • Contact Us

AVEO reports data from Ph I study of ficlatuzumab and cetuximab

by Bioblast Editor | Aug 10, 2020 | Biosimilars updates

AVEO Oncology releases its Q2 FY2020 earnings report. AVEO reported data from its Ph I study of ficlatuzumab and cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC) demonstrated that the products have an acceptable safety profile and...

FDA approves encorafenib/cetuximab combination

by Bioblast Editor | Apr 8, 2020 | Biosimilars updates

Pfizer announces the FDA has approved Braftovi® (encorafenib) in combination with Erbitux® (cetuximab) for the treatment of BRAF600E-mutant metastatic colorectal cancer after prior therapy.

Pre-clinical study results of APZ 001

by Bioblast Editor | Sep 18, 2018 | Biosimilars updates

Researchers release results of pre-clinical study of cetuximab candidate APZ001. 

Amgen discloses cetuximab biosimilar under development

by Bioblast Editor | Jan 10, 2018 | Biosimilars updates

Amgen discloses at JP Morgan Healthcare Conference that it is in process development for a cetuximab biosimilar.

MabTech announces successful Ph III trials of cetuximab

by Bioblast Editor | Jan 11, 2016 | Biosimilars updates

MabTech announces successful Chinese Ph III clinical trials for Sorrento’s “biosimilar/biobetter” cetuximab STI-001, and infliximab STI-002.

SUBSCRIBE TO PEARCE IP

Sign up to our latest news

Receive our Pearce IP Blog and weekly BioBlast® via email.

SUBSCRIBE
  • Our People
  • Our Capabilities
  • News
  • Blog
  • BioBlast®
  • Contact Us
  • Follow

Copyright © 2021 Pearce IP. All Rights Reserved.

Contact Us

Email: info@pearceIP.law
Tel: +61 (0) 2 9023 9988

For any general inquiries, please fill in the following contact form:

 





    Subscribe to our BioBlast®

    Fill in the form below to recieve our BioBlast™ Updates, Pearce IP Blog and other relevant industry updates.

     



      What emails do you want to receive?